PMID- 16306328
OWN - NLM
STAT- MEDLINE
DCOM- 20060926
LR  - 20220309
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 54 Suppl 2
DP  - 2005 Dec
TI  - Association of systemic chemokine concentrations with impaired glucose tolerance 
      and type 2 diabetes: results from the Cooperative Health Research in the Region 
      of Augsburg Survey S4 (KORA S4).
PG  - S11-7
AB  - Chemokines are crucial immune mediators in many physiological and 
      pathophysiological conditions. Chemokines have been hypothesized to be involved 
      in macrophage infiltration into adipose tissue in obesity and might therefore 
      play an important role in the development of obesity-related disorders like type 
      2 diabetes. Out of 1,653 individuals aged 55-74 years participating in a 
      population-based survey in southern Germany (the Kooperative Gesundheitsforschung 
      in der Region Augsburg [KORA] [Cooperative Health Research in the Region of 
      Augsburg] Survey S4, 1999-2001), 236 individuals with type 2 diabetes, 242 
      subjects with impaired glucose tolerance (IGT), and 244 normoglycemic control 
      subjects were studied for circulating concentrations of interleukin (IL)-8; 
      RANTES (regulated on activation, normal T-cell expressed, and secreted); 
      interferon-gamma-inducible protein-10 (IP-10), and eotaxin. Systemic 
      concentrations of RANTES were higher in individuals with IGT or type 2 diabetes 
      than in control subjects, whereas IL-8 levels were elevated in type 2 diabetic 
      patients only (P < 0.001 for all comparisons). IP-10 and eotaxin were not 
      significantly associated with IGT or type 2 diabetes. Adjustment for age, sex, 
      BMI, hypertension, LDL cholesterol, HDL cholesterol, uric acid, C-reactive 
      protein, and IL-6 did not alter these findings. Our findings indicate that RANTES 
      and IL-8 may be involved in the development of type 2 diabetes independent of 
      metabolic syndrome-related risk factors and of each other. There is no general 
      upregulation of chemokine production in type 2 diabetes, but rather an 
      association of the disease with specific members of the chemokine family.
FAU - Herder, Christian
AU  - Herder C
AD  - German Diabetes Clinic, German Diabetes Center, Leibniz Institute at 
      Heinrich-Heine University, Auf'm Hennekamp 65, 40225 Dusseldorf, Germany. 
      christian.herder@ddz.uni-duesseldorf.de
FAU - Haastert, Burkhard
AU  - Haastert B
FAU - Muller-Scholze, Sylvia
AU  - Muller-Scholze S
FAU - Koenig, Wolfgang
AU  - Koenig W
FAU - Thorand, Barbara
AU  - Thorand B
FAU - Holle, Rolf
AU  - Holle R
FAU - Wichmann, H-Erich
AU  - Wichmann HE
FAU - Scherbaum, Werner A
AU  - Scherbaum WA
FAU - Martin, Stephan
AU  - Martin S
FAU - Kolb, Hubert
AU  - Kolb H
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (CCL11 protein, human)
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CCL11)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokines, CC)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-8)
SB  - IM
MH  - Aged
MH  - Blood Pressure
MH  - Chemokine CCL11
MH  - Chemokine CCL5/blood
MH  - Chemokine CXCL10
MH  - Chemokines, CC/blood
MH  - Chemokines, CXC/blood
MH  - Cytokines/*blood
MH  - Diabetes Mellitus, Type 2/*blood/immunology
MH  - Female
MH  - Germany
MH  - Glucose Intolerance/*blood/immunology
MH  - Health Surveys
MH  - Humans
MH  - Interleukin-1/blood
MH  - Interleukin-8/blood
MH  - Male
MH  - Middle Aged
MH  - Reference Values
EDAT- 2005/11/25 09:00
MHDA- 2006/09/27 09:00
CRDT- 2005/11/25 09:00
PHST- 2005/11/25 09:00 [pubmed]
PHST- 2006/09/27 09:00 [medline]
PHST- 2005/11/25 09:00 [entrez]
AID - 54/suppl_2/S11 [pii]
AID - 10.2337/diabetes.54.suppl_2.s11 [doi]
PST - ppublish
SO  - Diabetes. 2005 Dec;54 Suppl 2:S11-7. doi: 10.2337/diabetes.54.suppl_2.s11.